Ameriprise Financial, Inc. · AMP · FY2025 Q4 · Calendar Q1 2026
Ameriprise enters 2026 with strong flows and higher investment needs
The supplied analysis supports a constructive operating picture: Ameriprise combined record scale, strong organic flows, adviser productivity, and product expansion with continued technology investment. The main counterweights are rate sensitivity, rising investment needs, and execution risks across banking, asset management, and distribution.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about AMP FY2025 Q4
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the supplied current analysis points to stronger momentum in client flows and wrap assets, broader product rollout, and higher investment intensity. It also shifts the focus toward execution around Signature Wealth, active ETFs, banking products, adviser compensation, and regional-bank consolidation.
Guidance delta
No new guidance was provided in the supplied analysis.
Key takeaways
- Management highlighted record AUM and revenue, strong client inflows, and double-digit EPS growth.
- Adviser recruitment, retention, productivity, and new products remain central to organic growth.
- Technology, AI, cloud, Signature Wealth, active ETFs, and banking offerings raise investment intensity while capital returns remain aggressive.
Management priorities
- Expand AI, digital, and cloud capabilities across the firm.
- Broaden Signature Wealth and managed SMA offerings, and add active ETFs in the US and EMEA.
- Grow checking, HELOC, and mortgage products while maintaining capital returns and share repurchases.
Follow AMP with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Sep 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Argus Research | Buy | Buy | Maintain | Jul 31, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 24, 2026 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Jul 24, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Jul 13, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Jul 13, 2026 |
| Morgan Stanley | Underweight | Underweight | Maintain | Jul 10, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 10, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | May 20, 2026 |
| William Blair | Market Perform | Outperform | Downgrade | Jul 25, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Jul 25, 2025 |
| UBS | Neutral | Buy | Downgrade | Jan 6, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Mar 27, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 1, 2023 |
| B of A Securities | Buy | Buy | Maintain | Sep 7, 2022 |
| Citigroup | Buy | Buy | Maintain | Jun 21, 2021 |
| Barclays | Overweight | Overweight | Maintain | Apr 12, 2021 |
| CFRA | Buy | Buy | Maintain | May 13, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Oct 26, 2017 |
| Deutsche Bank | Hold | Buy | Downgrade | Oct 14, 2016 |
| Wells Fargo | Market Perform | Outperform | Downgrade | Jan 13, 2016 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | Oct 12, 2015 |
| Sterne Agee | Neutral | Neutral | Maintain | Oct 13, 2014 |
Named analyst price targets
Upside is calculated against the persisted previous close $497.32. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Raymond James | Analyst unavailable | $638 | $558.26 | +28.3% | Aug 21, 2026 |
| Piper Sandler | Analyst unavailable | $518 | $506.76 | +4.2% | Jul 13, 2026 |
| Morgan Stanley | Michael Cyprys | $489 | $506.62 | -1.7% | Jul 10, 2026 |
| Jefferies | Suneet Kamath | $645 | $500.16 | +29.7% | Jul 10, 2026 |
| Piper Sandler | Crispin Love | $471 | $467.19 | -5.3% | May 4, 2026 |
| Morgan Stanley | Analyst unavailable | $467 | $479.63 | -6.1% | Apr 30, 2026 |
| BMO Capital | Brennan Hawken | $490 | $455.71 | -1.5% | Apr 24, 2026 |
| RBC Capital | Analyst unavailable | $560 | $456.59 | +12.6% | Apr 21, 2026 |
| Morgan Stanley | Analyst unavailable | $452 | $441.86 | -9.1% | Apr 10, 2026 |
| Raymond James | Wilma Burdis | $582 | $488.19 | +17.0% | Feb 11, 2026 |
| RBC Capital | Kenneth Lee | $605 | $529.47 | +21.7% | Feb 2, 2026 |
| Piper Sandler | John Barnidge | $530 | $521.36 | +6.6% | Jan 29, 2026 |
| Morgan Stanley | Analyst unavailable | $485 | $489.17 | -2.5% | Dec 22, 2025 |
| Evercore ISI | Analyst unavailable | $570 | $490.17 | +14.6% | Oct 9, 2025 |
| Morgan Stanley | Analyst unavailable | $484 | $486.62 | -2.7% | Oct 1, 2025 |
| Morgan Stanley | Michael Cyprys | $462 | $519.55 | -7.1% | May 15, 2025 |
| Morgan Stanley | Michael Cyprys | $509 | $514.04 | +2.3% | Oct 30, 2024 |
| Goldman Sachs | Alexander Blostein | $476 | $463.09 | -4.3% | Sep 25, 2024 |
| RBC Capital | Kenneth Lee | $500 | $432.05 | +0.5% | Jul 30, 2024 |
| UBS | Brennan Hawken | $495 | $429.25 | -0.5% | Jul 9, 2024 |
| Argus Research | Kevin Heal | $460 | $418.95 | -7.5% | May 6, 2024 |
| Morgan Stanley | Michael Cyprys | $445 | $412.86 | -10.5% | Apr 24, 2024 |
| Morgan Stanley | Michael Cyprys | $437 | $435.77 | -12.1% | Apr 9, 2024 |
| Piper Sandler | John Barnidge | $392 | $428.89 | -21.2% | Apr 5, 2024 |
| Morgan Stanley | Analyst unavailable | $345 | $320.45 | -30.6% | Jan 10, 2023 |
| UBS | Analyst unavailable | $370 | $324.71 | -25.6% | Jan 9, 2023 |
| Goldman Sachs | Analyst unavailable | $330 | $332.97 | -33.6% | Nov 23, 2022 |
| Morgan Stanley | Analyst unavailable | $340 | $316.94 | -31.6% | Nov 17, 2022 |
| Piper Sandler | Analyst unavailable | $220 | $223.12 | -55.8% | Jul 15, 2022 |
| Piper Sandler | Analyst unavailable | $231 | $238.27 | -53.6% | Jul 8, 2022 |
| Piper Sandler | John Barnidge | $253 | $235.1 | -49.1% | Jun 21, 2022 |
| Piper Sandler | Analyst unavailable | $275 | $274.33 | -44.7% | May 27, 2022 |
| UBS | Analyst unavailable | $350 | $267.4 | -29.6% | Apr 26, 2022 |
| Morgan Stanley | Analyst unavailable | $330 | $280.96 | -33.6% | Apr 26, 2022 |
| Jefferies | Suneet Kamath | $350 | $293.04 | -29.6% | Apr 9, 2022 |
| Piper Sandler | John Barnidge | $310 | $292.26 | -37.7% | Apr 6, 2022 |
Track every rating change on AMP the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAmeriprise Financial, Inc. is a holding company, which engages in providing financial planning, asset management, and insurance services to individuals, businesses, and institutions. It operates through the following business segments: Advice & Wealth Management, Asset Management, Retirement & Protection Solutions, and Corporate & Other. The Advice & Wealth Management segment consists of financial planning and advice, as well as full-service brokerage services for retail clients through financial advisors.…
Historical context
All AMP earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PUK Prudential plc | FY2026 Q2 · Calendar Q3 2026 | -40.9% | -0.5% | Prudential sustains growth and capital returns focus in H1 2026 |
| CM Canadian Imperial Bank of Commerce | FY2026 Q3 · Calendar Q3 2026 | +8.9% | -2.8% | CIBC Q3: Broad growth, resilient credit and expanded AI rollout |
| TD The Toronto-Dominion Bank | FY2026 Q3 · Calendar Q3 2026 | +13.8% | +1.4% | TD emphasizes growth investments alongside disciplined capital management |
| RY Royal Bank of Canada | FY2026 Q3 · Calendar Q3 2026 | +6.2% | -1.3% | RBC reports record Q3 earnings while investing for growth |
| AFRM Affirm Holdings, Inc. | FY2026 Q4 · Calendar Q3 2026 | +1230.3% | +0.3% | Affirm's most profitable quarter shifts focus to product execution |
Latest beats and misses
Who reports nextBeat on EPS
- CCLFY2026 Q3 · September 29, 2026+5.9% EPS+13.4% move
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
- SNXFY2026 Q3 · September 24, 2026+20.9% EPS-9.9% move
- DRIFY2027 Q1 · September 24, 20260.0% EPS-3.0% move
- CTASFY2027 Q1 · September 23, 2026+3.0% EPS-3.4% move
- PAYXFY2027 Q1 · September 23, 2026+1.5% EPS-8.8% move
Get the AMP recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-09-30T11:26:14.605297+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-30T11:26:14.602611+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-30. For educational purposes only; not investment advice.